Sanofi-Aventis to sue Cimex over generic Plavix

Swiss firm Cimex AG's clopidogrel, a generic form of Sanofi-Aventis' Plavix, has been approved in its home market. The French drug major, which originated the blockbuster blood clotting drug, has already filed legal action against Cimex and noted that the rival product contains a different salt of the active ingredient used in Plavix. Two marketing partners are expected to launch the agent in Germany. According to Cimex, applications for additional European countries are in preparation.